MERCK (MRK)
Pharmaceutical Preparations · market cap $364.4B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
- 2026-12-01 (est.)Phase 2 · Axatilimabimp 7/10
- 2026-12-05 (est.)Phase 2 · pembrolizumabimp 7/10
- 2026-12-11 (est.)Phase 2 · pembrolizumabimp 7/10
- 2026-12-15 (est.)Phase 2 · Infliximabimp 7/10
- 2026-12-16 (est.)Phase 2 · pembrolizumabimp 7/10
- 2026-12-22 (est.)Phase 2 · Belzutifanimp 7/10
- 2026-12-23 (est.)Phase 2 · Lenvatinibimp 7/10
- 2026-12-30 (est.)Phase 2 · Belzutifanimp 7/10
| Asset | Phase | Indication |
|---|---|---|
| V114 Non-adjuvanted | Phase 2 | Pneumococcal Infections |
| Lonafarnib | Phase 2 | Breast Cancer |
| Pemetrexed Cisplatin | Phase 2 | Non Small Cell Lung Cancer |
| EVX-01 | Phase 2 | Melanoma Stage IV |
| Decadron | Phase 3 | Malignant Neoplasms of Male Genital Organs |
| PembroRT | Phase 2 | Non-small Cell Lung Cancer, NSCLC |
| Brexucabtagene autoleucel (other names: brexu-cel, Tecartus) | Phase 2 | Recurrent Mantle Cell Lymphoma |
| MK1903 | Phase 2 | Dyslipidemia |
| MK-2206 | Phase 2 | PANCREAS |
| Elbasvir | Phase 3 | Hepatitis C |
| Peginterferon alfa-2a (Peg-IFN) | Phase 2 | Hepatitis C, Chronic |
| ANV600 | Phase 2 | Advanced Solid Tumor |
| Sevoflurane | Phase 3 | Muscle Relaxation |
| HIBERIX™ | Phase 3 | Pneumococcal Infections |
| Pembrolizumab/Favezelimab | Phase 2 | Colorectal Cancer |
| Pentacel™ | Phase 3 | Pneumococcal Infections |
| Pembrolizumab (for 30 minutes | Phase 2 | Breast Cancer |
| M-M-R™ II | Phase 3 | Pneumococcal Infections |
| Ritonavir-boosted protease inhibitor | Phase 2 | HIV |
| Uprifosbuvir (+) Grazoprevir (+) Ruzasvir | Phase 2 | Hepatitis C |
Daily closes through 2026-11-17. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for MRK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
